Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted fromin-vivo rat data?
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
In a drug discovery environment, reasonable go/no-go human in-vivo pharmacokinetic (PK) decisions must be made in a timely manner with a minimum amount of animal in-vivo or in-vitro data. We have investigated the accuracy of the in-vivo correlation between rat and human for the prediction of the total systemic clearance (CL), the volume of distribution at steady state (Vss), and the half-life (t1/2) using simple allometric scaling techniques. We have shown, using a large diverse set of drugs, that a fixed exponent allometric scaling approach can be used to predict human in-vivo PK parameters CL, Vss and t(1/2) solely from rat in-vivo PK data with acceptable accuracy for making go/no-go decisions in drug discovery. Human in-vivo PK predictions can be obtained using the simple allometric scaling relationships CL(Human) approximately = 40 CL(Rat) (L/hr), Vss(Human) approximately = 200 Vss(Rat) (L), and t1/2(Human) approximately = 4 t1/2(Rat) (hr). The average fold error for human CL predictions for N = 176 drugs was 2.25 with 79% of the drugs having a fold error less than 3. The average fold error for human Vss predictions for N = 144 drugs was 1.85 with 84% of the drugs having a fold error less than 3. The average fold error for human t1/2 predictions for N = 145 drugs was 2.05 with 76% of the drugs having a fold error less than 3. Using these simple allometric relationships, the sorting of drug candidates into a low/medium/high/very high human classification scheme was also possible from rat data. Since these simple allometric relationships between rat and human CL, Vss, and t1/2 are reasonably accurate, easy to remember and simple to calculate, these equations should be useful for making early go/no-go in-vivo human PK decisions for drug discovery candidates.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They reported that single-species scaling, particularly when anchored to physiologically based corrections, can yield acceptable predictions for many small molecules.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [62]
Citations
Cites
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232 · cited 1×
“The prediction of human in-vivo hepatic clearance (CLH) has been studied using several different humanized in-vitro systems such as, hepatic microsomes (14, 15), heterologously expressed cytochrome P450 (CYPs) enzymes (16) and hepatocytes (17 - 19).”
BackgroundThe Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987 · cited 7×
“Simple allometric methods using three animal species are thought not to be sufficiently accurate in predicting human drug half-lives to be of practical value (13,24,31).”
BackgroundMethodInfluentialThe prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
Sun, K. (2005) · Chinese New Drugs Journal · Cited by 762
Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648 · cited 3×
“Both methods are related to the standard allometric equation (25):”
BackgroundMethodPrediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., & Sugiyama, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00184-2 · Cited by 479 · cited 1×
“, well-stirred, parallel tube, or dispersion) for converting in-vitro intrinsic metabolic clearances (CLint) into in-vivo CLH values has been shown to be important for the predictive outcome of low and highclearance drugs (20).”
BackgroundPharmaceutical Statistics: Practical and Clinical Applications.
Wallenstein, S., & Bolton, S. (1986) · Journal of the American Statistical Association · doi:10.2307/2289267 · Cited by 430
Amidon, G. L., Sinko, P. J., & Fleisher, D. (1988) · Pharmaceutical Research · doi:10.1023/a:1015927004752 · Cited by 300
Pharmaceutical Statistics: Practical and Clinical Applications
Kershner, R. (1985) · Technometrics · doi:10.1080/00401706.1985.10488086 · Cited by 283
Linear Correlation of the Fraction of Oral Dose Absorbed of 64 Drugs Between Humans and Rats
Chiou, W. L., & Barve, A. (1998) · Pharmaceutical Research · doi:10.1023/a:1011981317451 · Cited by 257 · cited 2×
“This lack of correlation between rat and human oral bioavailabilities is speculated to be more likely due to factors such as drug formulation and metabolism differences than absorption factors, since literature data indicates that the in-vivo oral absorption in rats is a good early predictor of human oral absorption (…”
BackgroundMethodDesign of drugs involving the concepts and theories of drug metabolism and pharmacokinetics
Smith, D. A., Jones, B., & Walker, D. K. (1996) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199605)16:3<267::aid-med3>3.0.co;2-x · Cited by 239
Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics
Smith, D. A., Jones, B. C., & Walker, D. K. (1996) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199605)16:3<243::aid-med2>3.0.co;2-z · Cited by 237 · cited 3×
“The primary goal of this study was to determine if in-vivo rat PK parameters (F, fa' CL, Vss' and t l(2) could be used to predict human in-vivoPK parameters suchthat reasonable go/no-go decisions could be made in drug discovery programs.”
BackgroundInfluentialLombardo, F., Obach, R. S., Shalaeva, M. Y., & Gao, F. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0200409 · Cited by 213 · cited 1×
“Methods for the prediction of Vss> for neutral and basic drug candidates, using physicochemical measurements and serum protein binding data has been shown to be very close to 2 fold of the actual values (21).”
BackgroundChiou, W. L., Jeong, H. Y., Chung, S. M., & Wu, T. C. (2000) · Pharmaceutical Research · doi:10.1023/a:1007552927404 · Cited by 182 · cited 1×
“The in-vivo drug absorption (fa)measured in animals (rats and primates) has been shown to be agood predictor of in-vivo absorption in humans ( 48 - 51 ).”
BackgroundLav??, T., Coassolo, P., & Reigner, B. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936030-00003 · Cited by 162 · cited 1×
“Allometric scaling from three species has been combined with in-vitro human metabolic data (29).”
BackgroundLau, Y. Y., Sapidou, E., Cui, X., White, R. E., & Cheng, K.-C. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1446 · Cited by 140
The New Pre-Preclinical Paradigm: Compound Optimization in Early and Late Phase Drug Discovery
Caldwell, G. W., Ritchie, D. M., Masucci, J. A., Hageman, W., & Yan, Z. (2001) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026013394949 · Cited by 137 · cited 2×
“Since efficacy and safety properties are related partially to drug metabolism (DM) and pharmacokinetic (PK) properties of drug candidates, a variety of humanized in-vitro and in-vivo mammalian assays are used to screen drug discovery pipelines for deficient DMPK properties (6, 7).”
BackgroundComparison of Oral Absorption and Bioavailability of Drugs Between Monkey and Human
Chiou, W. L., & Buehler, P. W. (2002) · Pharmaceutical Research · doi:10.1023/a:1016169202830 · Cited by 123
The prediction of human clearance from hepatic microsomal metabolism data.
Obach, R. S. (2001) · PubMed · Cited by 119
The absolute oral bioavailability of selected drugs.
Sietsema, W. K. (1989) · PubMed · Cited by 109
Lavé, T., Dupin, S., Schmitt, C., Valles, B., Ubeaud, G., Chou, R. C., Jaeck, D., & Coassolo, P. (1997) · Pharmaceutical Research · doi:10.1023/a:1012036324237 · Cited by 106 · cited 1×
“The prediction of human in-vivo hepatic clearance (CL H ) has been studied using several different humanized in-vitro systems such as, hepatic microsomes (14, 15), heterologously expressed cytochrome P450 (CYPs) enzymes (16) and hepatocytes ( 17 - 19 ).”
BackgroundTarbit, M. H., & Berman, J. (1998) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(98)80017-3 · Cited by 106 · cited 1×
“(4) A verage -told error = 1n~: Ilog( Ypredicted / Y actuaJI”
BackgroundPreclinical Drug Metabolism in the Age of High-Throughput Screening: An Industrial Perspective
Rodrigues, A. D. (1997) · Pharmaceutical Research · doi:10.1023/a:1012105713585 · Cited by 98 · cited 2×
“(Method II) YHuman =YRat (WHuman/WRal (3) where Y is the PK parameter CL, Vss and t l /2' WHuman is the weight of a human and WRat is the weight of a rat.”
BackgroundMethodDrug metabolism and pharmacokinetics in drug discovery.
Roberts, S. A. (2003) · PubMed · Cited by 95
Allometric scaling of xenobiotic clearance: Uncertainty versus universality
Hu, T., & Hayton, W. L. (2001) · AAPS PharmSci · doi:10.1208/ps030429 · Cited by 93
Allometric issues in drug development†
Mahmood, I. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js9902163 · Cited by 91 · cited 5×
“Physiologically based modeling techniques (22) and allometric scaling methods (23,24) have been used to extrapolate both humanized in-vitro and in-vivo animal data to human DMPK parameters.”
BackgroundMethodInfluentialScaling basic toxicokinetic parameters from rat to man.
Bachmann, K., Pardoe, D., & White, D. (1996) · Environmental Health Perspectives · doi:10.1289/ehp.96104400 · Cited by 90 · cited 9×
“(39, 40) with additional data from other publications (22, 33 37).”
BackgroundMethodInfluentialInterspecies scaling of renally secreted drugs
Mahmood, I. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00525-6 · Cited by 88 · cited 1×
“Studies have shown that renally secreted drugs may not scale using simple allometric approaches ( 52 ).”
BackgroundPhysiologically Based Pharmacokinetic Model for Terbinafine in Rats and Humans
Hosseini-Yeganeh, M., & McLachlan, A. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.7.2219-2228.2002 · Cited by 80 · cited 1×
“Physiologically based modeling techniques (22) and allometric scaling methods (23,24) have been used to extrapolate both humanized in-vitro and in-vivo animal data to human DMPK parameters.”
MethodVožeh, S., Schmidlin, O., & Taeschner, W. (1988) · Clinical Pharmacokinetics · doi:10.2165/00003088-198815040-00005 · Cited by 73
Interspecies extrapolation of pharmacokinetics
Travis, C. C., White, R. K., & Ward, R. C. (1990) · Journal of Theoretical Biology · doi:10.1016/s0022-5193(05)80554-5 · Cited by 72 · cited 1×
“Assuming that the allometric coefficient and exponent are fixed values, pharmacokinetic values can be scaled from rats to humans as follows (42,43):”
BackgroundMahmood, I., & Balian, J. D. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00339-6 · Cited by 72 · cited 1×
“Most of these studies recommend that the data from two or more animal species be used for these predictions (32).”
BackgroundWajima, T., Fukumura, K., Yano, Y., & Oguma, T. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10242 · Cited by 72 · cited 2×
“, molecular weight, Log P and the number of hydrogen bond acceptors), can be used to predict human CL values better than multi-specie allometric methods (30).”
BackgroundMethodNovel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats
Cox, K. (1999) · Drug Discovery Today · doi:10.1016/s1359-6446(98)01299-9 · Cited by 71 · cited 1×
“In most cases, rats are the preferred specie for establishing an early PK profile of drug candidates (26).”
BackgroundAllometric Pharmacokinetic Scaling: Towards the Prediction of Human Oral Pharmacokinetics
Feng, M. R., Lou, X., Brown, R. R., & Hutchaleelaha, A. (2000) · Pharmaceutical Research · doi:10.1023/a:1007520818956 · Cited by 69 · cited 2×
“Physiologically based modeling techniques (22) and allometric scaling methods (23,24) have been used to extrapolate both humanized in-vitro and in-vivo animal data to human DMPK parameters.”
MethodThe Use of In Vitro Methods to Predict In Vivo Pharmacokinetics and Drug Interactions
Bachmann, K., & Ghosh, R. (2001) · Current Drug Metabolism · doi:10.2174/1389200013338504 · Cited by 64 · cited 2×
“tl12 Method I Method II (hr) Equation (11) b=O.”
BackgroundChiou, W. L., Robbie, G. J., Chung, S. M., Wu, T., & Ma, C. (1998) · Pharmaceutical Research · doi:10.1023/a:1011974226596 · Cited by 61 · cited 3×
“(28) and further examined here for a larger data set is more than adequate for making reasonable go/no-go drug clearance decisions in drug discovery.”
BackgroundMethodMahmood, I. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991773320 · Cited by 59 · cited 4×
“V~, Varea, and Vss) from animal data has been shown to accurately predict the human volume of distribution (31).”
BackgroundMethodInfluentialCaldwell, G. W. (2010) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/978160805204210401010607 · Cited by 55
Mahmood, I. (1998) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1998.tb06190.x · Cited by 53 · cited 3×
“However, studies have suggested that the mean residence time (MRT) for humans can be predicted using simple allometric methods and animal data (38).”
BackgroundMethodSimilarity in the linear and non-linear oral absorption of drugs between human and rat
Chiou, W. L., Ma, C., Chung, S. M., Wu, T. C., & Jeong, H. Y. (2000) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp38532 · Cited by 50
In vitro-in vivo correlation of the pharmacokinetics of vinpocetine.
Szakács, T., Veres, Z., & Vereczkey, L. (2001) · PubMed · Cited by 47
Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416
Sukbuntherng, J., Cropp, G., Hannah, A., Wagner, G. S., Shawver, L. K., & Antonian, L. (2001) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357011778232 · Cited by 45 · cited 1×
“The t'h data were assembled from an article by Bachmann et al. (39,40) with additional data from other publications (23, 25,30, 33 - 37 ).”
MethodPredicting drug pharmacokinetics in humans from in vitro metabolism studies
McGinnity, D. F., & Riley, R. J. (2001) · Biochemical Society Transactions · doi:10.1042/0300-5127:0290135 · Cited by 44
Risk Assessment of Environmental Chemicals
Fan, A. M., Howd, R. A., & Davis, B. J. (1995) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.35.040195.002013 · Cited by 41 · cited 1×
“Assuming that the allometric coefficient and exponent are fixed values, pharmacokinetic values can be scaled from rats to humans as follows (42,43):”
BackgroundPredicting drug pharmacokinetics in humans from in vitro metabolism studies
McGinnity, D. F., & Riley, R. J. (2001) · Biochemical Society Transactions · doi:10.1042/bst0290135 · Cited by 41 · cited 1×
“The prediction of human in-vivo hepatic clearance (CLH) has been studied using several different humanized in-vitro systems such as, hepatic microsomes (14, 15), heterologously expressed cytochrome P450 (CYPs) enzymes (16) and hepatocytes (17 - 19).”
BackgroundBachmann, K. (1989) · Journal of Applied Toxicology · doi:10.1002/jat.2550090509 · Cited by 39 · cited 5×
“(39, 40) with additional data from other publications (22, 33 37).”
BackgroundMethodInfluentialEstimating Xenobiotic Half-Lives in Humans from Rat Data: Influence of log P
Sarver, J. G., White, D. B., Erhardt, P., & Bachmann, K. A. (1997) · Environmental Health Perspectives · doi:10.1289/ehp.971051204 · Cited by 34
Beaumont, K. C., Harper, A., Smith, D. A., & Bennett, J. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00144-5 · Cited by 32 · cited 1×
“The t'h data were assembled from an article by Bachmann et al. (39,40) with additional data from other publications (23, 25,30, 33 - 37 ).”
MethodMahmood, I. (2000) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2000.16.2.143 · Cited by 31 · cited 1×
“Allometric scaling approaches also have been investigated using absolute oral bioavailability data from at least three different animal species (47).”
BackgroundSinko, P. J. (1999) · PubMed · Cited by 30
First Time in Human for GV196771: Interspecies Scaling Applied on Dose Selection
Iavarone, L., Hoke, J. F., Bottacini, M., Barnaby, R., & Preston, G. C. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008164 · Cited by 28
Lead optimization in 12 months? True confessions of a chemistry team
Macdonald, S. J. F., & Smith, P. W. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)01937-7 · Cited by 26 · cited 1×
“6741 VssRat (10) Using Method I, the log-log regression analysis of the experimental human t ,;, and rat t ,;, data is shown in Figure 3a and Table I.”
MethodDo Drug Metabolism and Pharmacokinetic Departments Make Any Contribution to Drug Discovery?
Smith, D. A., Schmid, E. F., & Jones, B. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241130-00001 · Cited by 23 · cited 2×
“The predictions of human PK parameters, from humanized in- vitro assays,have been extensively evaluated and utilized to varying degrees in drug discovery therapeutic projects (2, 10- 12 ).Humanized in- vitro assays have been used to predict the absolute oral bioavailabiltty (F), the total systemic clearance (Cl.), the…”
BackgroundInfluentialMasucci, J. A., Caldwell, G. W., & CHACON, E. J. G. (1999) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207302666220126185603 · Cited by 16
The Importance of Drug Metabolism Studies for Efficient Drug Discovery and Development.
Caldwell, J. (1996) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.11.119 · Cited by 11
Applied Pharmacokinetics in Drug Development: An Overview of Drug Discovery
Caldwell, G. W., Yan, Z., Masucci, J. A., Hageman, W., Leo, G. C., & Ritchie, D. M. (2003) · Pharmaceutical Development and Regulation · doi:10.1007/bf03257371 · Cited by 9
[Pharmacokinetic properties of rithmidazole upon single intravenous introduction].
Спасов, А. А., Stepanov, A. V., Smirnova, L. A., Petrov, V. I., & Ig, S. (2002) · PubMed · Cited by 1
Research works printed but not linked: 2
- Spasov, A. A.; Stepanov, A.V.; Smirnova, L. A.; Petrov, V. I.; Shabasheva, I. G. (2002). Pharmacokinetics of rhythmidazol upon single intravenous administration. Eksperimental’naya i Klinicheskaya Farmakologiya 65(3), 57–61.
- Vo_eh, S.; Schmidlin, O.; Taeschner, W. (1989). Pharmacokinetic drug Data. In: Clinical Pharmacokinetic Drug Data Handbook 1989. ADIS Press Limited, New Zealand, p. 1–38.
Cited by
Animal models of human disease: challenges in enabling translation
McGonigle, P., & Ruggeri, B. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.006 · Cited by 610
Obach, R. S., Lombardo, F., & Waters, N. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020479 · Cited by 462
“Previous reports have focused on prediction methods that utilize animal pharmacokinetic data (Caldwell et al., 2004; Ward and Smith, 2004a,b; Jolivette and Ward, 2005; Evans et al., 2006; Mahmood et al., 2006; Martinez et al., 2006; Tang and Mayersohn, 2006; Fagerholm, 2007; McGinnity et al., 2007)…”
MethodAnimal to human translation: a systematic scoping review of reported concordance rates
Leenaars, C. H. C., Kouwenaar, C., Stafleu, F. R., Bleich, A., Ritskes-Hoitinga, M., De Vries, R. B. M., & Meijboom, F. L. B. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1976-2 · Cited by 314
“the percentage < twofold error versus the correlation [50], and for the sensitivity, specificity, positive predictive value and negative predictive value [51].”
A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer
Whitley, M. J., Cardona, D. M., Lazarides, A. L., Spasojevic, I., Ferrer, J. M., Cahill, J., Lee, C.-L., Snuderl, M., Blazer, D. G., Hwang, E. S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad0293 · Cited by 296
Hayes' Principles and Methods of Toxicology
(2014) · CRC Press eBooks · doi:10.1201/b17359 · Cited by 280
Metadata
- Authors
- Caldwell, G. W., Masucci, J. A., Yan, Z., & Hageman, W.
- Affiliations
- Janssen Research & Development (United States) (US)
- ORCID
- Yan, Zhengyin
- Venue
- European Journal of Drug Metabolism and Pharmacokinetics
- Published
- 2004-06
- Volume
- 29
- Issue
- 2
- Pages
- 133-143
- ISSN
- 0378-7966 (ISSN-L)
- 2107-0180
- OpenAlex
- W2019418677
- Cited by
- 148
- References
- 56
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 4 · 2023: 7 · 2022: 2 · 2021: 6 · 2020: 9 · 2019: 4 · 2018: 7 · 2017: 10 · 2016: 8 · 2015: 5 · 2014: 8 · 2013: 7 · 2012: 8
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Drug Metabolism and Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- allometric scaling, pharmacokinetic prediction, rat-to-human extrapolation, half-life, go/no-go decisions, drug discovery
- MeSH terms
- Algorithms, Animals, Half-Life, Humans, Pharmacokinetics, Predictive Value of Tests, Regression Analysis, Species Specificity, Drug Design, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.